Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Lee Jackson | Mar 11, 2015 at 9:40 AM EDT

4 Top Pharmaceutical Stocks to Buy for Market Safety

A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to…

Chris Lange | Mar 11, 2015 at 9:15 AM EDT

Short Sellers Get More Aggressive on Big Biotech

24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with…

Chris Lange | Mar 9, 2015 at 10:25 AM EDT

Can AcelRx Overcome Yet Another FDA Roadblock?

AcelRx Pharmaceuticals announced an update on the timing and potential content of its resubmission of the New Drug Application (NDA)…

Lee Jackson | Mar 6, 2015 at 8:20 AM EST

The Next 3 Likely Biotech Buyout Candidates

Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics…

Chris Lange | Mar 5, 2015 at 10:40 AM EST

Just How Expensive Is the Pharmacyclics Buyout?

News finally broke late Wednesday that there was an official buyout of Pharmacyclics in the works by AbbVie for $21…

Chris Lange | Mar 4, 2015 at 3:28 PM EST

Novogen Makes Big Step In Fighting Brain Cancer

ThinkstockNovogen Limited (NASDAQ: NVGN) confirmed Wednesday morning that one of its lead candidate products, TRXE-009, has shown potential to become…

Lee Jackson | Mar 4, 2015 at 8:35 AM EST

The 5 Most Loved Biotech Stocks of Portfolio Managers

A big part of the Nasdaq is biotech, and a new report from Cowen details the stocks that big money…

Chris Lange | Mar 3, 2015 at 2:47 PM EST

Oncolytics Newest Orphan Drug Designation

ThinkstockOncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for Reolysin.…

Chris Lange | Mar 3, 2015 at 12:25 PM EST

Key Analyst Weighs In on Boston Scientific Acquisition

Merrill Lynch has weighed in on Boston Scientific acquiring the American Medical Systems urology portfolio of Endo International.

Paul Ausick | Mar 3, 2015 at 11:45 AM EST

Is the Actavis $21 Billion Bond Sale Just the First?

Actavis launched second-largest ever bond sale Monday to raise $21 billion to pay for its acquisition of Allergan.

Lee Jackson | Mar 3, 2015 at 8:50 AM EST

4 High-Yield Health Care Real Estate Investment Trusts to Buy Now

Here are four high-yielding health care real estate investment trust currently rated Overweight by RBC analysts.

Lee Jackson | Mar 3, 2015 at 8:25 AM EST

4 Biotechs Expected to See Huge Buying on PowerShares Rebalance

All the major money management firms that run exchange traded funds have to do regular quarterly rebalances to reset their…

Chris Lange | Mar 2, 2015 at 4:54 PM EST

Are Mylan Earnings Enough?

ThinkstockMonday after the markets closed, Mylan, Inc. (NASDAQ: MYL) reported its fourth-quarter financial results as in line with estimates. Specifically…

Chris Lange | Feb 26, 2015 at 3:35 PM EST

Has Biocept Reached an Inflection Point?

Biocept has seen its stock move up over 200% in the past week, only to give back about 20% in…

Lee Jackson | Feb 26, 2015 at 10:20 AM EST

5 Health Care Stocks That Are Possible Buyout Candidates

24/7 Wall St. has screened the RBC list of potential takeover candidates for the higher profile and more well-known health…

1 … 268 269 270 271 272 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

4 Top Pharmaceutical Stocks to Buy for Market Safety

Short Sellers Get More Aggressive on Big Biotech

Can AcelRx Overcome Yet Another FDA Roadblock?

The Next 3 Likely Biotech Buyout Candidates

Just How Expensive Is the Pharmacyclics Buyout?

Novogen Makes Big Step In Fighting Brain Cancer

The 5 Most Loved Biotech Stocks of Portfolio Managers

Oncolytics Newest Orphan Drug Designation

Key Analyst Weighs In on Boston Scientific Acquisition

Is the Actavis $21 Billion Bond Sale Just the First?

4 High-Yield Health Care Real Estate Investment Trusts to Buy Now

4 Biotechs Expected to See Huge Buying on PowerShares Rebalance

Are Mylan Earnings Enough?

Has Biocept Reached an Inflection Point?

5 Health Care Stocks That Are Possible Buyout Candidates

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Health and Healthcare Articles

All Health and Healthcare Articles

4 Top Pharmaceutical Stocks to Buy for Market Safety

Short Sellers Get More Aggressive on Big Biotech

Can AcelRx Overcome Yet Another FDA Roadblock?

The Next 3 Likely Biotech Buyout Candidates

Just How Expensive Is the Pharmacyclics Buyout?

Novogen Makes Big Step In Fighting Brain Cancer

The 5 Most Loved Biotech Stocks of Portfolio Managers

Oncolytics Newest Orphan Drug Designation

Key Analyst Weighs In on Boston Scientific Acquisition

Is the Actavis $21 Billion Bond Sale Just the First?

4 High-Yield Health Care Real Estate Investment Trusts to Buy Now

4 Biotechs Expected to See Huge Buying on PowerShares Rebalance

Are Mylan Earnings Enough?

Has Biocept Reached an Inflection Point?

5 Health Care Stocks That Are Possible Buyout Candidates

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

Featured Reads

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later